What is the 13F Pro Quality Score for VTGN?

13F Pro ranks Vistagen Therapeutics, Inc. (VTGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VTGN's current score at https://13fpro.ai/research/VTGN (free sign-up required for the full ranking).

Where does 13F Pro source VTGN data?

All Vistagen Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Vistagen Therapeutics, Inc. files with the SEC under CIK 1411685. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VTGN in?

Vistagen Therapeutics, Inc. (VTGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VTGN research updated on 13F Pro?

VTGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vistagen Therapeutics, Inc.(VTGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1411685 VTGN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $16.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VTGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Vistagen Therapeutics, Inc. (VTGN), a Healthcare sector company. VTGN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $16.4m in revenue. Based on the latest XBRL financial filings (Q4 2026), Vistagen Therapeutics, Inc. reports quarterly revenue of $465.0K, net income of $-16.3M, free cash flow of $-16.2M. Top institutional holders of VTGN by reported 13-F value include ORBIMED ADVISORS, TCG Crossover Management,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. VTGN trades on the Nasdaq exchange and files with the SEC under CIK 1411685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vistagen Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q4 2026

$465.0K

Net Income

Q4 2026

$-16.3M

Free Cash Flow

Q4 2026

$-16.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+659.0% YoY

$1.3MFY 2026

FY21 $1.1MFY22 $1.1MFY23 $-227.0KFY26 $1.3M

Net Income

-17.6% YoY

$-69.7MFY 2026

FY21 $-17.9MFY22 $-47.8MFY23 $-59.2MFY26 $-69.7M

Operating Income

-21.7% YoY

$-72.1MFY 2026

FY21 $-17.9MFY22 $-47.8MFY23 $-59.3MFY26 $-72.1M

EPS (Diluted)

+78.5% YoY

$-1.83FY 2026

FY21 —FY22 —FY23 $-8.51FY26 $-1.83

Total Assets

+130.3% YoY

$48.6MFY 2026

FY21 $108.3MFY22 $74.6MFY23 $21.1MFY26 $48.6M

Op. Cash Flow

-33.6% YoY

$-66.4MFY 2026

FY21 $-12.1MFY22 $-45.3MFY23 $-49.7MFY26 $-66.4M

Metric	FY 2026	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$1.3M +659.0%	$-227.0K -120.5%	$1.1M +1.8%	$1.1M	$0.00	—
Net Income	$-69.7M -17.6%	$-59.2M -24.0%	$-47.8M -166.3%	$-17.9M +13.7%	$-20.8M +15.5%	$-24.6M
Operating Income	$-72.1M -21.7%	$-59.3M -24.0%	$-47.8M -166.4%	$-17.9M +13.8%	$-20.8M +15.3%	$-24.6M
EPS (Diluted)	$-1.83 +78.5%	$-8.51	—	—	—	—
Total Assets	$48.6M +130.3%	$21.1M -71.7%	$74.6M -31.1%	$108.3M +1775.9%	$5.8M -58.8%	$14.0M
Operating Cash Flow	$-66.4M -33.6%	$-49.7M -9.9%	$-45.3M -274.8%	$-12.1M +23.4%	$-15.8M -8.5%	$-14.5M

AI Insight: VTGN Financial Trends

Vistagen remains pre-revenue with accelerating cash burn and equity eroding from $105M to $36M over two years.

• Operating income deteriorated from -$12M in Q2 2024 to -$20M in Q4 2025, widening losses despite flat zero revenue.

• Shareholder equity contracted 66% from $105M in Q2 2024 to $36M in Q1 2026, driven by cumulative operating losses.

• Operating cash outflow averaged -$14M per quarter over last eight quarters, with no revenue generation or positive FCF inflection.

⚠ Equity runway declining materially; at current burn rate (~$16M/quarter), cash runway appears constrained absent capital raise.

⚠ No revenue or clinical milestone announcements evident in financial data; pre-revenue status persists without disclosed progress.

AI Insight: VTGN Ratio Trends

Vistagen's profitability deteriorated sharply through 2025, with ROE collapsing from -41.0% in Q2 2024 to -183.3% in Q1 2026.

• ROE worsened every quarter: -41.0% (Q2 2024) → -183.3% (Q1 2026), indicating accelerating net losses relative to equity.

• ROA declined from -37.8% (Q2 2024) to -96.0% (Q3 2025), reflecting deepening operating losses on shrinking asset base.

• ROIC fell from -46.3% (Q2 2024) to -82.4% (Q1 2025) before data gaps, signaling value destruction on invested capital.

⚠ No profitability or leverage metrics available for most recent quarter (Q1 2026 TTM); data gaps obscure current capital structure.

⚠ Consistent sequential deterioration across all return metrics through Q1 2026 suggests ongoing cash burn with no visible inflection.

Get alerted when VTGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vistagen Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VTGN

ORBIMED ADVISORS LLC
$1.7M3,060,000 sh
TCG Crossover Management, LLC
$1.5M2,676,580 sh
VANGUARD CAPITAL MANAGEMENT LLC
$900.4K1,574,200 sh
ADAR1 Capital Management, LLC
$429.3K751,141 sh
Ikarian Capital, LLC
$296.7K519,077 sh
TWO SIGMA INVESTMENTS, LP
$268.4K469,619 sh
GEODE CAPITAL MANAGEMENT, LLC
$259.2K453,391 sh
BlackRock, Inc.
$256.3K448,507 sh
MILLENNIUM MANAGEMENT LLC
$246.0K430,404 sh
LUMINUS MANAGEMENT LLC
$226.3K396,053 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$1.7M	3,060,000
TCG Crossover Management, LLC	$1.5M	2,676,580
VANGUARD CAPITAL MANAGEMENT LLC	$900.4K	1,574,200
ADAR1 Capital Management, LLC	$429.3K	751,141
Ikarian Capital, LLC	$296.7K	519,077
TWO SIGMA INVESTMENTS, LP	$268.4K	469,619
GEODE CAPITAL MANAGEMENT, LLC	$259.2K	453,391
BlackRock, Inc.	$256.3K	448,507
MILLENNIUM MANAGEMENT LLC	$246.0K	430,404
LUMINUS MANAGEMENT LLC	$226.3K	396,053

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VTGN on your watchlist

Track score changes the day Vistagen Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VTGN a good stock to buy?

13F Pro's AI-powered analysis of Vistagen Therapeutics, Inc. (VTGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VTGN are available on the VTGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VTGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VTGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vistagen Therapeutics, Inc.'s investment landscape.